Molecular Imaging: Page 2

PET can predict MACE in cardiac sarcoidosis patients
By Will Morton
PET imaging can help identify whether cardiac sarcoidosis patients are at higher risk of major adverse cardiac events (MACE).
August 9, 2024
A graphical abstract of the study. Image courtesy of JACC: Cardiovascular Imaging.
PET tracer performs well in prostate cancer trial
By Will Morton
An experimental PET radiotracer that targets gastrin-releasing peptide receptors (GRPR) on prostate cancer cells has shown promise in a phase II clinical trial in Australia.
August 8, 2024
Fused PET/CT, maximum-intensity projection PET, and lung-windowed CT images (from left to right) from Cu-64 SAR-BBN (top row) and Ga-68 PSMA-11 (bottom row) PET/CT study of patient demonstrating left subpleural lesion (arrows, SUVmax of 10 at 1 hour) that showed Cu-64 SAR-BBN uptake but no Ga-68 PSMA-11 uptake. PSA was 1.84 ng/mL at time of imaging. This patient underwent lobectomy, with histopathology demonstrating metastatic prostate cancer.
Study explores neurologic problems in Pluvicto patients
By Will Morton
Men treated with Lu-177 PSMA-617 for prostate cancer may experience neurologic problems after starting therapy, but most are mild and manageable through conservative methods.
August 2, 2024
A graphical abstract of the study.
New theranostics pairing tested in breast cancer patients
By Kate Madden Yee
A new theranostics pairing of molecular imaging and radioligand therapy shows promise as a treatment option for patients with metastatic breast cancer, researchers have found.
July 31, 2024
Breast Cancer
FES-PET effective for staging breast cancer in phase II trial
By Will Morton
F-18 fluroestradiol (FES)-PET/CT appears as effective as standard imaging for staging women with estrogen receptor-positive locally advanced breast cancer or evaluating suspected recurrence.
July 26, 2024
The patient was a woman in her 50s with suspected recurrence of invasive lobular breast cancer. A, maximum intensity projection image from FDG-PET/CT demonstrating avid foci in the chest (red arrow). Transaxial CT (B) and transaxial fused FDG-PET/CT image (C) showing that the chest avidity corresponds to FDG-avid lung nodules (red arrows) suspicious for malignancy. The lung nodule was subsequently biopsied but found to represent benign granulomatous inflammation and thus a false positive on FDG-PET/CT. D, maximum intensity projection image from FES-PET/CT demonstrating multifocal uptake suspicious for malignancy. E, transaxial CT and fused FES-PET/CT demonstrating no FES-avidity in the biopsy proven benign granulomatous lung nodules (red arrows), thus true negative on FES-PET/CT. FES-avidity in nodes (white arrow) is suspicious for malignancy. F, transaxial CT and fused FES-PET/CT demonstrates gastric avidity (blue arrow) suspicious for malignancy. G, transaxial CT and fused FES PET/CT demonstrates FES-avid osseous foci (yellow arrow) suspicious for malignancy. This osseous focus was subsequently biopsied and proved to be an osseous metastasis and thus true positive on FES-PET/CT.
PET/MRI rules out tau protein in late-life depression
By Will Morton
A PET/MRI study has provided insights into the neurobiology of late-life depression, finding tau protein is not involved in the condition.
July 25, 2024
Coronal and axial slice of the average cortical F-18 MK-6240 SUVR [standard uptake value ratio] image for each study population. SUVR images were corrected for partial volume effects and masked with the gray matter mask used for volume of interest delineation. Overall tau accumulation is comparable between the late-life depression (LLD, middle column) and non-depressed cognitively unimpaired comparison (HC, left column) groups, while abnormal tau accumulation, which is most pronounced in the mesial temporal lobe, can be seen in the mild cognitive impairment due to Alzheimer's disease group (right column). Image and caption courtesy of the American Journal of Geriatric Psychiatry.
Tau PET identifies grey matter atrophy in retired athletes
By Will Morton
Flortaucipir PET imaging is able to identify neuropathological brain changes in retired contact sport athletes at risk of neurodegeneration.
July 24, 2024
Example of the flortaucipir tau-PET signal and distribution of low grey matter volume in a single former athlete. Spatial maps of the flortaucipir tau-PET standardized update value (SUVR) (top) and the reduced grey matter volumes showed in blue and defined as voxels with a w-score of >1.5 below the mean (bottom) in a single former athlete. Image courtesy of the Journal of Neurology.
PET/MRI superior to PET/CT in cancer patients
By Will Morton
FDG-PET/MRI is comparable or superior in diagnostic performance to FDG-PET/CT across a range of cancers and endpoints.
July 18, 2024
Pet Scan
FAPI-SPECT reveals damage to myocardium after heart attack
By Will Morton
Technetium-99m (Tc-99m) FAPI-SPECT shows promise as a tool for assessing cellular and structural changes in the myocardium after heart attack.
July 16, 2024
Emergency percutaneous coronary intervention images, Tc-99m MIBI perfusion images and Tc-99m FAPI images of STEMI patients. In STEMI patients, there is a localized yet inhomogeneous uptake of Tc-99m FAPI. Notably, the extent of Tc-99m FAPI uptake significantly surpasses the area of perfusion defects. Despite similarities in coronary artery lesions (culprit vessels identified as the left anterior descending artery in image A and the right coronary artery in image B, white arrows), and comparable myocardial perfusion impairment, patients with larger Tc-99m FAPI uptake areas exhibit ventricular remodeling. Image courtesy of the Journal of Nuclear Cardiology.
Bone marrow disorders associated with SARs in Lutathera patients
By Will Morton
Pretreatment bone marrow disorders may predict which patients are at risk for severe adverse reactions (SARs) when treated with lutetium-177 DOTATATE.
July 15, 2024
2024 07 11 Sa Rs Patients Lu 177 Dotatate Voter
The rise of theranostics: Part 5 -- Advice from center administrators
By Liz Carey
Want to launch theranostics at your hospital and cancer center? An SNMMI 2024 session provided key planning steps.
July 12, 2024
Nuclear medicine technologist and theranostics practice administrator Dmitry Beyder (left) and Vikas Prasad, MD, PhD (right), lead the theranostics center at Barnes-Jewish Hospital/Washington University in Saint Louis, MO. Image courtesy of Washington University.
LAFOV PET/CT feasible in infants with neuroblastoma
By Will Morton
Long axial field-of-view (LAFOV) PET/CT scanners offer shorter procedure times and avoid the need for sedation or general anesthesia when imaging young children with neuroblastoma.
July 9, 2024
Hospital Baby Nurse
Previous Page
Page 2 of 596
Next Page